Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 392.7% in September

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 94,600 shares, an increase of 392.7% from the August 31st total of 19,200 shares. Approximately 8.9% of the shares of the company are short sold. Based on an average daily volume of 448,700 shares, the short-interest ratio is currently 0.2 days.

Allarity Therapeutics Stock Performance

ALLR stock remained flat at $2.23 during mid-day trading on Friday. The company’s stock had a trading volume of 88,952 shares, compared to its average volume of 210,758. Allarity Therapeutics has a 12 month low of $1.78 and a 12 month high of $666.00. The business has a 50 day moving average price of $0.77 and a 200-day moving average price of $1.58.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.11) earnings per share for the quarter. As a group, analysts predict that Allarity Therapeutics will post -78.08 EPS for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.